Keytruda (pembrolizumab) significantly extends survival without disease worsening in adults with relapsed or refractory classical Hodgkin’s Lymphoma (cHL), compared to treatment with Adcetris (brentuximab vedotin), interim data from a Phase 3 pivotal trial show. “Patients with classical Hodgkin lymphoma are generally young and when they do not achieve remission following standard treatment, their cancer is challenging to treat,” Jonathan Cheng, MD, vice president of oncology clinical research, at Merck Research Laboratories, said in a press release. Keytruda, by Merck, is a PD-1 inhibitor indicated for several types of blood and solid tumors. The medicine was granted accelerated approval in March 2017 by the U.S. Food and Drug Administration (FDA) for the treatment of adults and children with refractory cHL who…
April 14, 2020April 14, 2020